Catalog No.
DHD48409
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
ERBB3, HER3, Proto-oncogene-like protein c-ErbB-3, Tyrosine kinase-type cell surface receptor HER3, Receptor tyrosine-protein kinase erbB-3
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P21860
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
29Z6
Clone ID
29Z6
Note
For research use only. Not suitable for clinical or therapeutic use.
Clinicopathological significance of concurrent ErbB receptor expression in human meningioma., PMID:37719042
HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target., PMID:37898642
The novel antibody fusion protein rhNRG1-HER3i promotes heart regeneration by enhancing NRG1-ERBB4 signaling pathway., PMID:38150867
ErbB3 Governs Endothelial Dysfunction in Hypoxia-Induced Pulmonary Hypertension., PMID:38214194
The Therapeutic Significance of HER3 in Non-small Cell Lung Cancer (NSCLC): A Review Study., PMID:38231075
ERBB3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive Prostate Cancer and is Associated with a Unique AR Activity Signature., PMID:38306015
Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in Gastric Cancer., PMID:38339127
Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC., PMID:38369013
Neuregulin-1 and ALS19 (ERBB4): at the crossroads of amyotrophic lateral sclerosis and cancer., PMID:38369520
Expert Consensus on the Diagnosis and Treatment of NRG1/2 Gene Fusion Solid Tumors., PMID:38414979
Molecular and Clinical Portrait of HER2-low Invasive Lobular Carcinomas., PMID:38428737
Targeting HER2/HER3 co-mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy., PMID:38441358
A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer., PMID:38605180
DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors., PMID:38632563
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study., PMID:38748939
HER3 (ERBB3) amplification in liposarcoma - a putative new therapeutic target?, PMID:38760830
Inhibition of EGFR/ErbB does not protect against C. difficile toxin B., PMID:38798529
Trans-activating mutations of the pseudokinase ERBB3., PMID:38806620
BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study., PMID:38823410
Long road towards effective HER3 targeting in breast cancer., PMID:38885540
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response., PMID:38992028
HER3 receptor and its role in the therapeutic management of metastatic breast cancer., PMID:39020378
Targeting undruggable phosphatase overcomes trastuzumab resistance by inhibiting multi-oncogenic kinases., PMID:39094301
ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance., PMID:39098760
EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate., PMID:39128771
Correction: The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation., PMID:39392382
Leucine-Rich Alpha-2-Glycoprotein 1 Promotes Metastatic Colorectal Cancer Growth Through Human Epidermal Growth Factor Receptor 3 Signaling., PMID:39393543
Antitumor activity of PAbs generated by immunization with a novel HER3-targeting protein-based vaccine candidate in preclinical models., PMID:39479017
A review of recombinant HER3 affibodies with an effective diagnostic view of cancer cells., PMID:39485069
YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers., PMID:39495173
Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas., PMID:39572979
PlexinD1 is a driver and a therapeutic target in advanced prostate cancer., PMID:39748059
Exploring novel therapeutic targets in small bowel adenocarcinoma: insights from claudin 18.2, nectin-4, and HER3 expression analysis., PMID:39754977
CD44v, S1PR1, HER3, MET and cancer-associated amino acid transporters are promising targets for the pancreatic cancers characterized using mAb., PMID:39757718
Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer., PMID:39908431
Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan., PMID:39931207
Human epidermal growth factor receptor 3 expression in patients with epithelial ovarian cancer: a potential target for ovarian mucinous and clear cell carcinoma., PMID:39937426
Full-length transcriptome atlas of gallbladder cancer reveals trastuzumab resistance conferred by ERBB2 alternative splicing., PMID:39948369
Systemic HER3 ligand-mimicking nanobioparticles enter the brain and reduce intracranial tumour growth., PMID:39984637
HER3-targeting Antibody-drug Conjugates Therapy for Solid Tumors: Recent Advances and Future Potentials., PMID:39995133
Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies., PMID:40046734
Emerging importance of HER3 in tumorigenesis and cancer therapy., PMID:40087402
Establishment and characterization of novel patient-derived esophageal tumoroids with long-term cultivability., PMID:40108093
Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors., PMID:40178042
HER3: Unmasking a twist in the tale of a previously unsuccessful therapeutic pursuit targeting a key cancer survival pathway., PMID:40290122
Ophthalmological manifestations and plasma markers of inflammation in Ebola survivors in post-treatment era., PMID:40301432
Integrated Two-Analyte Population Pharmacokinetics Model of Patritumab Deruxtecan (HER3-DXd) Monotherapy in Patients with Solid Tumors., PMID:40408047
Efficient Design of Affilin® Protein Binders for HER3., PMID:40429825
Patritumab deruxtecan induces immunogenic cell death., PMID:40458967
For research use only. Not for human or drug use.
